<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654249</url>
  </required_header>
  <id_info>
    <org_study_id>THD_LIGA_RCT</org_study_id>
    <nct_id>NCT02654249</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Trial About THD Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids</brief_title>
  <acronym>THD-LIGA</acronym>
  <official_title>Prospective Multicenter Randomized Trial About Transanal Hemorrhoidal Dearterialization With Mucopexy (THD) Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates postoperative pain, morbidity, recurrence and quality of life, comparing&#xD;
      two different strategies in the treatment of grade III and IV hemorrhoids: transanal&#xD;
      hemorrhoidal dearterialization with mucopexy (THD) versus hemorrhoidectomy by Ligasure™.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transanal hemorrhoidal dearterialization (THD)‪ uses a specially developed anoscope combined&#xD;
      with a Doppler transducer to identify the hemorrhoidal arteries. A suture ligation is&#xD;
      performed to effectively decrease the blood flow to the hemorrhoidal plexus. In case of&#xD;
      redundant prolapse, the prolapsed mucosa is lifted (mucopexy). THD procedure is performed&#xD;
      without any incisions or removal of the hemorrhoidal tissue and moreover the suture line is&#xD;
      above the dentate line, so post-operative pain and morbidities seem to be minimized in these&#xD;
      patients. This technique differs from Ligasure hemorrhoidectomy, which focuses on excising&#xD;
      the hemorrhoidal tissue.&#xD;
&#xD;
      This prospective, randomized, multicenter and controlled trial compares post-operative pain,&#xD;
      morbidities, quality of life, fecal incontinence and recurrence rate in patients treated for&#xD;
      grade III and IV hemorrhoids with THD with mucopexy versus Ligasure hemorrhoidectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>Post-operative pain by simple verbal numerical scale (0-10), the Andersen scale (0-5) and the taken pain medicacions will be recorded by the patients on a specific book during the first thirty days after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 1 month and at 1 and 2 years after surgery</time_frame>
    <description>Quality of life by Short Form 12 (SF-12) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific disabilities (fecal incontinence and costipation)</measure>
    <time_frame>At the day 15, 30 and at 1 and 2 years after surgery</time_frame>
    <description>Fecal incontinence by Vaizey Score and need of laxatives. Anorecatal manometry and endoanal ultrasonography will be performed two month after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>Dindo classification of complicacions will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhoid recurrence</measure>
    <time_frame>At 1 and 2 years after surgery</time_frame>
    <description>rectal bleeding, anal pain, mucosal prolaps will be invastigated one year after hemorroidectomy. Needing of further surgery for hemorrhoids recurrence will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction after surgery</measure>
    <time_frame>At the day 15, 30 and at 1 and 2 years after surgery</time_frame>
    <description>A scale of 0-3 (0, not satisfied; 1 few satisfied, 2 satisfied, 3, very satisfied) will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>THD and mucopexy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transanal hemorrhoidal dearterialization + mucopexy (THD).</intervention_name>
    <description>Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.</description>
    <arm_group_label>THD and mucopexy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ligasure™ hemorrhoidectomy</intervention_name>
    <description>Excisional hemorroidectomy performed with Ligasure™</description>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THD anoscope and doppler</intervention_name>
    <description>An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure</description>
    <arm_group_label>THD and mucopexy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ligasure Vessel Sealing</intervention_name>
    <description>A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy</description>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with grade III and IV hemorrhoids according to Goligher classification&#xD;
&#xD;
          -  Patients ASA I, II or III and adequate hematological, renal and hepatic function&#xD;
&#xD;
          -  Patients who signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Altered cognitive state that prevents collaboration in the study or patients who can&#xD;
             neither read nor write&#xD;
&#xD;
          -  Fecal incontinence&#xD;
&#xD;
          -  Anal sphincter lesions&#xD;
&#xD;
          -  Recurrent hemorrhoids after previous surgical tratment&#xD;
&#xD;
          -  Previous anorectal surgery except banding, botulinum toxin injection and thrombectomy&#xD;
             for hemorrhoid thrombosis&#xD;
&#xD;
          -  Injection sclerotherapy during the last five years&#xD;
&#xD;
          -  Concomitant anorectal disease (anal fistula, anal fissure, anal stenosis, rectocele,&#xD;
             enterocele, anal condilomatosis).&#xD;
&#xD;
          -  Concomitant diagnosis of functional pelvic floor disease, inflammatory bowel disease&#xD;
             and previous pelvic radiotherapy&#xD;
&#xD;
          -  Concomitant diagnosis of colorectal neoplasia or other neoplasia&#xD;
&#xD;
          -  Patients ASA IV, V&#xD;
&#xD;
          -  NSAIDs, Paracetamol, Tramadol, Metamizol and Petidine allergy&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Rejection of the patient to sign the consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Biondo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Valdeorras</name>
      <address>
        <city>O Barco de Valdeorras</city>
        <state>Ourense</state>
        <zip>32300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galdakano Usansolo Hospital</name>
      <address>
        <city>Bizkaia</city>
        <state>Pais Vasco</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valle d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Leon</name>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Sebastiano Biondo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hemorrhoids grade III and IV</keyword>
  <keyword>transanal hemorrhoidal dearterialization</keyword>
  <keyword>hemorroidectomy</keyword>
  <keyword>THD</keyword>
  <keyword>LigaSure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

